We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN - Free Report) closed the most recent trading day at $9.33, moving +1.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.24%, while the tech-heavy Nasdaq appreciated by 0.36%.
Heading into today, shares of the pharmaceutical company had gained 47.83% over the past month, outpacing the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. On that day, Organon is projected to report earnings of $0.84 per share, which would represent a year-over-year decline of 17.65%. Simultaneously, our latest consensus estimate expects the revenue to be $1.47 billion, showing a 3.12% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.38 per share and a revenue of $6.17 billion, representing changes of -7.65% and -0.76%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. Currently, Organon is carrying a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 2.73 right now. This represents a discount compared to its industry average Forward P/E of 15.96.
Also, we should mention that OGN has a PEG ratio of 0.81. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services was holding an average PEG ratio of 1.4 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Rises Higher Than Market: Key Facts
Organon (OGN - Free Report) closed the most recent trading day at $9.33, moving +1.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.24%, while the tech-heavy Nasdaq appreciated by 0.36%.
Heading into today, shares of the pharmaceutical company had gained 47.83% over the past month, outpacing the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. On that day, Organon is projected to report earnings of $0.84 per share, which would represent a year-over-year decline of 17.65%. Simultaneously, our latest consensus estimate expects the revenue to be $1.47 billion, showing a 3.12% drop compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.38 per share and a revenue of $6.17 billion, representing changes of -7.65% and -0.76%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. Currently, Organon is carrying a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 2.73 right now. This represents a discount compared to its industry average Forward P/E of 15.96.
Also, we should mention that OGN has a PEG ratio of 0.81. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services was holding an average PEG ratio of 1.4 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.